企業プロフィール
BeyondSpring, Inc. 株価・ニュース・カタリスト
- ティッカー:
- BYSI
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.71 USD (-15.21%)
終値
最終更新: 2026年8月17日
69.9M USD
時価総額
株価変動の要因
Following the latest company update, “BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update”, BYSI closed down 15.2% at $0.7115 on Aug 17, 2026. The move occurred in the trading session associated with this earnings update.
企業概要
Clinical-Stage Oncology Company
BeyondSpring is a clinical-stage biopharmaceutical company developing therapies intended to improve outcomes for patients with cancer. Its lead program, plinabulin, is being evaluated across treatment settings where immune activation and combination therapy may enhance antitumor activity.
Plinabulin
Plinabulin is a small-molecule GEF-H1 activator designed to promote dendritic-cell maturation and stimulate antitumor immune responses. The candidate has been administered to more than 700 patients and is being developed for use with chemotherapy, immune checkpoint inhibitors, antibody-drug conjugates, and other cancer therapies.
Post-Immunotherapy NSCLC Strategy
BeyondSpring is developing plinabulin for patients with advanced non-small cell lung cancer whose disease has progressed after PD-1 or PD-L1 therapy. Clinical work has evaluated plinabulin with docetaxel and with a triplet regimen combining plinabulin, docetaxel, and pembrolizumab.
DUBLIN-4 Confirmatory Program
The planned DUBLIN-4 study is a randomized, double-blind Phase 3 trial expected to enroll approximately 442 patients with non-squamous, EGFR wild-type NSCLC following progression on immunotherapy. The study is designed to confirm the survival and tolerability findings observed in the earlier DUBLIN-3 program.
Combination Optionality
BeyondSpring is also studying the potential for plinabulin to complement antibody-drug conjugates, radiation, and other immune-based approaches. Preclinical research supports a strategy of using plinabulin to broaden immune engagement and potentially improve the durability of combination regimens.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。